| Progress Healthcare Llc | |
| 328 Broadway, Suite 209, Lynn, Massachusetts 1904 | |
| (781) 363-0058 | |
| Not Available |
| Name | Progress Healthcare Llc |
|---|---|
| Location | 328 Broadway, Suite 209, Lynn, Massachusetts |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
| Medicare ID | 227729 |
| Ownership Type | Proprietary |
| Service Area Zip Codes |
| NPI Number | 1396274916 |
| Organization Name | PROGRESS HEALTHCARE LLC |
| Address | 118 Franklin St Fl 3, Lynn, MA 01902 |
| Phone Number | 781-363-0058 |
News Archive
PrognosDx Health, Inc. announced today that in an independent research study published online in the Journal of Clinical Oncology, cellular levels of histone modifications define previously unrecognized subsets of patients with pancreatic cancer with distinct epigenetic phenotypes and clinical outcomes.
Regulus Therapeutics Inc. today announced the publication of new results in the journal Nature Biotechnology by Regulus scientists and collaborators. The new study demonstrated that systemic treatment of a microRNA therapeutic targeting microRNA-10b in tumor-bearing mice inhibits breast cancer metastasis. Cancer-related metastasis is a major cause of mortality and current cancer treatments have limited utility suppressing the metastatic spread of cancer cells. microRNA therapeutics targeting miR-10b represent a promising approach for the discovery and development of a novel anti-metastatic agent.
New research finds saliva testing has a high sensitivity for detecting severe acute respiratory syndrome 2 (SARS-CoV-2) in both symptomatic and asymptomatic patients.
Researchers from the University of Notre Dame have announced a breakthrough approach to allergy treatment that inhibits food allergies, drug allergies, and asthmatic reactions without suppressing a sufferer's entire immunological system.
› Verified 7 days ago
| Quality Rating: | Not Available* |
| * This measure currently does not have data or provider has been certified/recertified for less than 6 months. | |
News Archive
PrognosDx Health, Inc. announced today that in an independent research study published online in the Journal of Clinical Oncology, cellular levels of histone modifications define previously unrecognized subsets of patients with pancreatic cancer with distinct epigenetic phenotypes and clinical outcomes.
Regulus Therapeutics Inc. today announced the publication of new results in the journal Nature Biotechnology by Regulus scientists and collaborators. The new study demonstrated that systemic treatment of a microRNA therapeutic targeting microRNA-10b in tumor-bearing mice inhibits breast cancer metastasis. Cancer-related metastasis is a major cause of mortality and current cancer treatments have limited utility suppressing the metastatic spread of cancer cells. microRNA therapeutics targeting miR-10b represent a promising approach for the discovery and development of a novel anti-metastatic agent.
New research finds saliva testing has a high sensitivity for detecting severe acute respiratory syndrome 2 (SARS-CoV-2) in both symptomatic and asymptomatic patients.
Researchers from the University of Notre Dame have announced a breakthrough approach to allergy treatment that inhibits food allergies, drug allergies, and asthmatic reactions without suppressing a sufferer's entire immunological system.
› Verified 7 days ago
News Archive
PrognosDx Health, Inc. announced today that in an independent research study published online in the Journal of Clinical Oncology, cellular levels of histone modifications define previously unrecognized subsets of patients with pancreatic cancer with distinct epigenetic phenotypes and clinical outcomes.
Regulus Therapeutics Inc. today announced the publication of new results in the journal Nature Biotechnology by Regulus scientists and collaborators. The new study demonstrated that systemic treatment of a microRNA therapeutic targeting microRNA-10b in tumor-bearing mice inhibits breast cancer metastasis. Cancer-related metastasis is a major cause of mortality and current cancer treatments have limited utility suppressing the metastatic spread of cancer cells. microRNA therapeutics targeting miR-10b represent a promising approach for the discovery and development of a novel anti-metastatic agent.
New research finds saliva testing has a high sensitivity for detecting severe acute respiratory syndrome 2 (SARS-CoV-2) in both symptomatic and asymptomatic patients.
Researchers from the University of Notre Dame have announced a breakthrough approach to allergy treatment that inhibits food allergies, drug allergies, and asthmatic reactions without suppressing a sufferer's entire immunological system.
› Verified 7 days ago
All Care Vna-greater Lynn Inc Location: 210 Market Street, Lynn, Massachusetts 1901 Ratings: Phone: (781) 598-2454 | |
Seraphic Springs Healthcare Location: 425 Western Avenue, Lynn, Massachusetts 1904 Ratings: NA Phone: (781) 581-2471 | |
Multicultural Home Care, Inc Location: 330 The Lynnway, Suite 103, Lynn, Massachusetts 1902 Ratings: Phone: (781) 593-7174 | |
Able Home Care, Llc Location: 270 Union Street, Suite 201, Lynn, Massachusetts 1901 Ratings: Phone: (781) 581-1181 | |
Neighborhood Home Care Llc Location: 270 Union Street, Ste #313, Lynn, Massachusetts 1901 Ratings: NA Phone: (781) 592-0511 | |
Ideal Health Care System Inc Location: 181 Union Street, Lynn, Massachusetts 1901 Ratings: NA Phone: (781) 477-9688 |